The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based chemotherapy (PLT).
 
Vincenza Conteduca
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen-Cilag; Sanofi/Aventis
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen-Cilag; Sanofi/Aventis
 
Loredana Puca
No Relationships to Disclose
 
Sheng-Yu Ku
No Relationships to Disclose
 
Judy Hess
No Relationships to Disclose
 
Megan Kearney
Employment - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
 
Luisa Fernandez
Employment - Epic Sciences
 
Rohan Bareja
No Relationships to Disclose
 
Panagiotis J. Vlachostergios
Honoraria - Dava Oncology
 
Michael Sigouros
No Relationships to Disclose
 
Juan Miguel Mosquera
No Relationships to Disclose
 
Andrea Sboner
No Relationships to Disclose
 
David M. Nanus
Consulting or Advisory Role - Roche/Genentech
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Zenith Epigenetics (Inst)
 
Olivier Elemento
No Relationships to Disclose
 
Ryan Dittamore
Employment - Epic Sciences
Leadership - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
Patents, Royalties, Other Intellectual Property - Patents Pending
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Dendreon; Endocyte; Genentech; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; QED Therapeutics; Sanofi; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
 
Himisha Beltran
Consulting or Advisory Role - Abbvie; Astellas Pharma; Genzyme; GlaxoSmithKline; Janssen Oncology
Research Funding - Abbvie/Stemcentrx (Inst); Janssen (Inst); Lilly (Inst)